Abeona Therapeutics Appoints Keith A. Goldan to Board

Experienced CFO joins biotech company's leadership team to advance strategic and financial goals.

Apr. 7, 2026 at 2:07pm

Got story updates? Submit your updates here. ›

A photorealistic studio still-life featuring a stack of financial reports, a pen, and a calculator on a clean, monochromatic background, symbolizing the financial leadership and corporate governance that will guide Abeona Therapeutics through its next phase of growth.Abeona Therapeutics bolsters its board with the addition of an experienced financial executive to help guide the company's strategic and operational priorities.Cleveland Today

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective April 1, 2026. Goldan, who will also serve as Chairman of Abeona's Audit Committee, brings over two decades of financial leadership experience across publicly traded biotech and pharmaceutical companies.

Why it matters

Goldan's appointment reflects Abeona's focus on strengthening its leadership team to support the company's growth as a commercial-stage biotech firm, particularly as it continues to build momentum for the US launch of its first approved product, ZEVASKYN.

The details

Goldan currently serves as Chief Financial Officer of Syndax Pharmaceuticals, where he has provided leadership through the company's first two product approvals and commercialization. Prior to that, he held CFO roles at Optinose, Fibrocell, NuPathe, PuriCore, and Biosyn, leading finance, accounting, IT, HR, and corporate development functions. Across these roles, Goldan has successfully raised capital, executed M&A transactions, and built infrastructure to support product launches.

  • Goldan's appointment to Abeona's Board of Directors was effective as of April 1, 2026.

The players

Abeona Therapeutics Inc.

A commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona's ZEVASKYN is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).

Keith A. Goldan

An accomplished financial leader with over two decades of experience across publicly traded commercial-stage biotechnology and specialty pharmaceutical companies. He currently serves as Chief Financial Officer of Syndax Pharmaceuticals.

Michael Amoroso

Chairman of Abeona's Board of Directors.

Got photos? Submit your photos here. ›

What they’re saying

“On behalf of the Board, we are delighted to welcome Keith to Abeona. Keith's deep experience in capital markets, corporate development, and operational scaling will be an invaluable voice as we continue to position Abeona for growth as a commercial-stage biotech company.”

— Michael Amoroso, Chairman of Abeona's Board of Directors

“I am excited to join the Board of Directors at Abeona at this important time in the organization's growth as commercial momentum continues to build for its first US launch. I look forward to partnering with the talented leadership team at Abeona to advance strategic priorities and drive value for patients and shareholders.”

— Keith A. Goldan

What’s next

Goldan will begin serving on Abeona's Board of Directors and as Chairman of the Audit Committee immediately.

The takeaway

Abeona's appointment of an experienced financial executive like Keith Goldan to its Board of Directors signals the company's commitment to strengthening its leadership and infrastructure as it transitions to a commercial-stage biotech firm with the launch of its first approved product.